Steven Cohen's PVLA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 88,160 shares of Palvella Therapeutics, Inc. (PVLA) worth $10.99 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Steven Cohen has maintained this position in PVLA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 10,863 shares. Largest reduction occurred in Q4 2025, reducing 240,012 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Palvella Therapeutics (PVLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Palvella Therapeutics (PVLA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +10,863 | Add 14.05% | 88,160 | $124.65 |
| Q4 2025 | -240,012 | Reduce 75.64% | 77,297 | $104.67 |
| Q3 2025 | +317,309 | New Buy | 317,309 | $62.69 |
Steven Cohen's Palvella Therapeutics Investment FAQs
Steven Cohen first purchased Palvella Therapeutics, Inc. (PVLA) in Q3 2025, acquiring 317,309 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Palvella Therapeutics, Inc. (PVLA) for 3 quarters since Q3 2025.
Steven Cohen's largest addition to Palvella Therapeutics, Inc. (PVLA) was in Q3 2025, adding 317,309 shares worth $19.89 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 88,160 shares of Palvella Therapeutics, Inc. (PVLA), valued at approximately $10.99 M.
As of the Q1 2026 filing, Palvella Therapeutics, Inc. (PVLA) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Palvella Therapeutics, Inc. (PVLA) was 317,309 shares, as reported at the end of Q3 2025.